<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796198</url>
  </required_header>
  <id_info>
    <org_study_id>COS16102007</org_study_id>
    <nct_id>NCT00796198</nct_id>
  </id_info>
  <brief_title>Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure</brief_title>
  <official_title>A Pilot Study on the Effects of Cosopt on IOP Lowering and Ocular Diastolic Perfusion Pressure in Patients Not Controlled With Xalatan Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Studies suggest that patients with low diastolic velocity and high resistivity&#xD;
      index in the ophthalmic artery had more progressive visual fields, the investigators&#xD;
      hypothesize therefore that addition of Cosopt to Latanoprost could improve ocular diastolic&#xD;
      perfusion pressure (ODPP).&#xD;
&#xD;
      Objective: To evaluate the effects of Cosopt on ODPP in patients not adequately controlled&#xD;
      with latanoprost alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty patients with primary open angle glaucoma (POAG) treated with Xalatan for whom the&#xD;
      monotherapy was not sufficient to achieve the target IOP, will be included in the study. Non&#xD;
      responders were defined when IOP was &gt; 20 mmHg or if the IOP reduction was less than 25% from&#xD;
      the baseline IOP. Patients will be classified as having POAG when they had a typical&#xD;
      glaucomatous visual field and/or a typical abnormal optic nerve head, open angle at&#xD;
      gonioscopy, IOP &gt; 21 mmHg with no treatment and no clinically apparent secondary cause for&#xD;
      their glaucoma (EGS guidelines).&#xD;
&#xD;
      Visual fields will be assessed by an Humphrey Field Analyzer 750 (HFA, Humphrey, Inc, CA,&#xD;
      USA), 24-2 SITA (Swedish Interactive Threshold Algorithm) standard. A glaucomatous visual&#xD;
      field defect was defined as: 1) three adjacent points depressed by 5 dB, with one of the&#xD;
      points depressed by at least 10 dB; 2) two adjacent points depressed by 10 dB; or 3) a 10 dB&#xD;
      difference across the nasal horizontal meridian in two adjacent points. None of the points&#xD;
      could be edge points unless immediately above or below the nasal horizontal meridian. In&#xD;
      addition, visual field testing was considered reliable only when false-negative responses&#xD;
      were less than 30% and fixation losses were less than 20% on HFA.&#xD;
&#xD;
      The abnormal optic nerve head classification was based on the presence of an optic rim notch&#xD;
      or of diffuse / generalized loss of optic rim tissue, vertical cup/disc diameter ratio&#xD;
      asymmetry unexplained by side differences in optic disc size, disc haemorrhage.&#xD;
&#xD;
      In each centre, patient's recruitment will start as soon as the ethical committee will&#xD;
      approve the protocol. Each sites will recruit 10 patients (5 + 5).&#xD;
&#xD;
      Cosopt will be added to Xalatan when Xalatan is effective but not sufficient to reach the&#xD;
      target pressure (Add group) (n = 25), while when Xalatan is effective and sufficient to reach&#xD;
      the target pressure no other medication will be added (control group) (n = 25).&#xD;
&#xD;
      (EGS guidelines: Target pressure is a subjective value that none is able to assess (until&#xD;
      now!). Efficacy of a drug: when the medication can decrease IOP as described in the phase&#xD;
      three of their clinical trial. Not sufficient: when the medication is effective but is not&#xD;
      able to reach the target IOP.)&#xD;
&#xD;
      Each patient will be submitted to three different visits:&#xD;
&#xD;
        -  Baseline visit: Systemic Pressure, IOP, VF, HRF, Visual Acuity, ophthalmic examination&#xD;
           with corneal central thickness (CCT)&#xD;
&#xD;
        -  Visit at 1 month: Systemic Pressure , IOP, Visual Acuity, ophthalmic examination&#xD;
&#xD;
        -  Visit at 3 months: Systemic Pressure, IOP , HRF, Visual Acuity, ophthalmic examination&#xD;
           (+ CCT) ODPP will be calculated by: &quot;systemic diastolic pressure - IOP&quot; at each session.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">July 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effects of Cosopt on ODPP in patients not adequately controlled with latanoprost alone</measure>
    <time_frame>baseline, at 1 and 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of Cosopt on IOP lowering in patients not adequately controlled with latanoprost alone.</measure>
    <time_frame>baseline, at 1 and 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Xalatan+Cosopt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cosopt will be added to Xalatan when Xalatan is effective but not sufficient to reach the target pressure (Add group) (n = 25)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xalatan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>when Xalatan is effective and sufficient to reach the target pressure no other medication will be added (control group) (n = 25)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalatan+Cosopt</intervention_name>
    <description>Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm</description>
    <arm_group_label>Xalatan+Cosopt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalatan</intervention_name>
    <description>Xalatan ophthalmic solution one drop at 10pm</description>
    <arm_group_label>Xalatan</arm_group_label>
    <arm_group_label>Xalatan+Cosopt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  POAG patients with a pattern deviation score (or its equivalent) ranging from 2.5 dB&#xD;
             to 6.0 dB will be included in the study. This will ensure that patients with&#xD;
             early/mid-stage glaucoma will be homogeneously collected; avoids advanced glaucoma in&#xD;
             which OBF may behave as a different disease state.&#xD;
&#xD;
          -  Best-corrected visual acuity will be of 0.5 or better with an ametropia &lt;5D - Dioptric&#xD;
             transparency, non smokers.&#xD;
&#xD;
          -  Age will be between 45 and 65 years.&#xD;
&#xD;
        Exclusion Criteria:n&#xD;
&#xD;
          -  Normal tension glaucoma, ocular hypertension, cardiovascular and/or metabolic diseases&#xD;
             (known to affect blood flow, as diabetes and polycythemia)&#xD;
&#xD;
          -  Visual field defects other than glaucoma; use of vasoactive and/or anti-hypertensive&#xD;
             drugs (systemic beta-blocker), use of acetazolamide&#xD;
&#xD;
          -  Hypersensibility and/or contraindications to any of the molecules studied&#xD;
&#xD;
          -  Previous ocular surgery&#xD;
&#xD;
          -  Pregnant or nursing women and use of one of drugs for erectile dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresa Rolle, MD, Assistent Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turin, Department of Clinical Physiopathology, Section of Ophthalmology, Eye Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Rolle, MD, Assistent Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turin, Department of Clinical Physiopathology-Section of Ophthalmology-Eye Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teresa Rolle, MD</last_name>
    <phone>00390115666032</phone>
    <email>teresa.rolle@unito.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Michele Vetrugno, MD</last_name>
      <phone>00 39 080 5592525</phone>
      <email>: m.vetrugno@oftalmo.uniba.it</email>
    </contact>
    <investigator>
      <last_name>Michele Vetrugno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chieti</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Marco Ciancaglini, MD</last_name>
      <phone>0039 0871 358410</phone>
      <email>m.ciancaglini@unich.it</email>
    </contact>
    <investigator>
      <last_name>Marco Ciancaglini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Genova</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Michele Iester, MD</last_name>
      <phone>00 39 010 3538469</phone>
      <email>iester@unige.it</email>
    </contact>
    <investigator>
      <last_name>Michele Iester, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Siena</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Paolo Frezzotti, MD</last_name>
      <phone>00 39 0577 233360</phone>
      <email>frezzottip@unisi.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Frezzotti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Turin</name>
      <address>
        <city>Turin</city>
        <zip>10143</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Teresa Rolle, MD</last_name>
      <phone>00390115666032</phone>
      <email>teresa.rolle@unito.it</email>
    </contact>
    <investigator>
      <last_name>Teresa Rolle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>November 21, 2008</study_first_submitted>
  <study_first_submitted_qc>November 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2008</study_first_posted>
  <last_update_submitted>November 24, 2008</last_update_submitted>
  <last_update_submitted_qc>November 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Rolle Teresa, MD,</name_title>
    <organization>University of Turin, Department of di Physiopathology Clinic-Section of Ophthalmology-Eye Clinic</organization>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Intraocular pressure</keyword>
  <keyword>Ocular diastolic perfusion pressure</keyword>
  <keyword>Dorzolamide/timolol Fixed combination</keyword>
  <keyword>Heidelberg Retina Flowmeter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

